Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 12.0% in December

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 5,120,000 shares, an increase of 12.0% from the November 30th total of 4,570,000 shares. Based on an average daily trading volume, of 805,900 shares, the short-interest ratio is currently 6.4 days. Currently, 9.3% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AGIO. Leerink Partnrs downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Raymond James reiterated an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. Scotiabank lifted their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Finally, Royal Bank of Canada upped their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $56.33.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $37,000. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals during the 2nd quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 363 shares in the last quarter. CWM LLC lifted its stake in shares of Agios Pharmaceuticals by 554.7% in the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Agios Pharmaceuticals during the third quarter worth about $146,000.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO opened at $33.03 on Tuesday. The firm has a fifty day moving average of $48.89 and a 200 day moving average of $46.16. The firm has a market cap of $1.88 billion, a PE ratio of 2.91 and a beta of 0.80. Agios Pharmaceuticals has a one year low of $20.96 and a one year high of $62.58.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.